In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

VisionCare Ophthalmic Technologies closes its $31mm Series E round

Executive Summary

VisionCare Ophthalmic Technologies Inc. (implantable ophthalmic devices) has raised $31mm through its Series E venture round. Saints Capital led and was joined by current shareholders Pitango Venture Capital, Three Arch Partners, Onset Ventures, and Newbury Acquisitions Fund/Infinity CSVC Management, and new backers Giza Ventures (which contributes a board member), General I Financial Holdings, and BSI SA. VisionCare will use the funds to launch its telescope prosthesis for end-stage AMD, for sales and marketing, and to continue developing new visual prosthetic devices for retinal disorders.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies